Agreement between the CDMOs comprises spray drying manufacturing services in the UK
cc-by-sa/2.0 - Sanofi, Rookwood Way (Haverhill) by Hugh Venables - geograph.org.uk/p/4693137
Catalent has announced that an agreement with Sanofi Active Ingredient Solutions—the industrial CDMO platform of Sanofi—gives the company access to spray drying manufacturing services for its clients at Sanofi’s Haverhill facility in the UK.
Headquartered in New Jersey (US) Catalent is now able to offer spray drying solutions from early-phase development through clinical supply, and all the way to fully scaled-up commercial finished dose form manufacturing in Europe.
“Sanofi Haverhill is our centre of excellence for spray drying technology. The site has over a decade of experience in spray drying operations for commercial manufacture. We welcome the relationship with Catalent and are delighted that Catalent is investing in the innovation and resources at our UK facility,” said Philippe Clavel, Head of Sanofi Active Ingredient Solutions.
Building on the agreement, Catalent extends its global spray drying offering by making available to customers the dedicated use of the existing Niro PSD2 and PSD4 spray driers at the facility.
This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site
"This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site with expertise in commercial-scale spray-dried dispersions, which are frequently used today to overcome the solubility challenges with many new medicines,” said Jonathan Arnold, President of Catalent’s Oral Drug Delivery business unit.
The equipment is supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations as well as a secondary vacuum dryer.
Catalent will also have access to the facility’s integrated quality control and analytical capabilities with scientific support resources, enabling an end-to-end approach for customers.
Earlier this year, Catalent announced a $40M investment in its Winchester, Kentucky facility that includes adding commercial-scale spray drying with high-potent handling capabilities, as well as other increases to the site’s capacity and its formulation and controlled-release tablet and capsule manufacturing capabilities.
The Winchester facility will work alongside the Sanofi Haverhill site to enable transfer and scale-up of spray drying programs from Catalent’s specialised early-stage clinical development sites located in San Diego, California and Nottingham, UK.